An exciting prospect is the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors which, when added to statins, seem to result in a more effective reduction of LDL-C192,193, with potential beneficial effect in stroke risk reduction194–199. The gene discussed is PCSK9; the disease is Stroke.